[go: up one dir, main page]

CO4700289A1 - TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY - Google Patents

TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY

Info

Publication number
CO4700289A1
CO4700289A1 CO95058767A CO95058767A CO4700289A1 CO 4700289 A1 CO4700289 A1 CO 4700289A1 CO 95058767 A CO95058767 A CO 95058767A CO 95058767 A CO95058767 A CO 95058767A CO 4700289 A1 CO4700289 A1 CO 4700289A1
Authority
CO
Colombia
Prior art keywords
tachycinin
amida
antagonists
sulfur
methyl
Prior art date
Application number
CO95058767A
Other languages
Spanish (es)
Inventor
So Young Ko
Christopher Walpole
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CO4700289A1 publication Critical patent/CO4700289A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

1. UN COMPUESTO DE LA FORMULA I FIGURA 1 EN LA QUE R1 ES FENILO MONO O DISUSTITUIDO POR UNO O DOS MIEMBROS SELECCIONADOS DEL GRUPO QUE CONSISTE DE HALOGENO, NITRO, CIANO, TRIFLUOROMETILO, HIDROZI, METOXI, HIDROXIMETILO, METOXIMETILO, METOXICARBO- LO, CARBAMOILO Y N-METILCARBAMOILO, n ES CERO o 1 X1 ES OXIGENO, AZUFRE O =NCN, X2 Y X3 SON CADA UNO INDEPENDIENTEMENTE OXIGENO O AZUFRE, R2 ES HIDROGENO O METILO, R3 ES FENILO, FENILO SUSTITUIDO CON HALO, 2-NAFTI- LO, 1H-INDOL-3-ILO O 1-METIL-INDOL-3-ILO, Z ES -N(CH3)o -CH2-, R4 ES FENILO, 3,5-BIS(TRIFLUOROMETIL)FENILO O PI- RIDILO, Y R5 ES HIDROGENO, FENILO 3,5-BIS(TRIFLUOROMETIL) FENILO O PIRIDILO, POR LO QUE, CUANDO X3 ES AZUFRE, Z ES -N(CH3)-, O UNA SAL DE ADICION DE ACIDO DEL MISMO.1. A COMPOUND OF FORMULA I FIGURE 1 IN WHICH R1 IS MONO PHENYLUS OR DISSTITUTED BY ONE OR TWO SELECTED MEMBERS OF THE GROUP THAT CONSISTS OF HALOGEN, NITRO, CIANO, TRIFLUOROMETILO, HIDROZIME, METHYLOX, CARBAMOIL AND N-METHYL CARBAMOYL, n IS ZERO or 1 X1 IS OXYGEN, SULFUR O = NCN, X2 AND X3 ARE EACH INDEPENDENTLY OXYGEN OR SULFUR, R2 IS HYDROGEN OR METHYL, R3 IS FENYL-FUTHYL-SUBSTITUTE LO, 1H-INDOL-3-ILO OR 1-METHYL-INDOL-3-ILO, Z ES -N (CH3) or -CH2-, R4 ES FENILO, 3,5-BIS (TRIFLUOROMETIL) FENILO OR PI- RIDILO, AND R5 IS HYDROGEN, PHENYL 3,5-BIS (TRIFLUOROMETIL) PHENYL OR PYRIDILE, SO, WHEN X3 IS SULFUR, Z IS -N (CH3) -, OR AN ADDITION SALT OF THE SAME ACID.

CO95058767A 1994-12-13 1995-12-12 TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY CO4700289A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
CO4700289A1 true CO4700289A1 (en) 1998-12-29

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95058767A CO4700289A1 (en) 1994-12-13 1995-12-12 TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY

Country Status (17)

Country Link
EP (1) EP0797583A1 (en)
JP (1) JPH10511935A (en)
AR (1) AR001332A1 (en)
AU (1) AU4343796A (en)
BR (1) BR9509997A (en)
CA (1) CA2204130A1 (en)
CO (1) CO4700289A1 (en)
CZ (1) CZ179097A3 (en)
FI (1) FI971685L (en)
HU (1) HUT77002A (en)
IL (1) IL116323A0 (en)
NO (1) NO972526D0 (en)
PE (1) PE38997A1 (en)
PL (1) PL320217A1 (en)
SK (1) SK74697A3 (en)
TR (1) TR199501568A2 (en)
WO (1) WO1996018643A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
ATE333879T1 (en) * 1996-10-07 2006-08-15 Merck Sharp & Dohme CNS-PENETRATING NK-1 RECEPTOR ANTAGONISTS AS AN ANTIDEPRESSANT AND/OR ANXIOLYTIC
WO2000048623A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
RU2309953C2 (en) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Aryl- and heteroaryl-substituted tetrahydroisoquinolines, pharmaceutical composition and method for treatment based on thereof
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CN100430401C (en) 2000-07-11 2008-11-05 Amr科技公司 Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
KR101389246B1 (en) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
UA95454C2 (en) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (en) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
MX2009007200A (en) 2007-01-10 2009-07-15 Angeletti P Ist Richerche Bio Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors.
CN101641099A (en) 2007-01-24 2010-02-03 葛兰素集团有限公司 Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (en) 2008-03-03 2011-05-19 タイガー ファーマテック Tyrosine kinase inhibitor
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (en) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CN102595902B (en) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro Isoquinolines and their uses
CN102638982B (en) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3, Crystal form of 4-tetrahydroisoquinoline and its use
JP5099731B1 (en) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション Substituted piperidines that increase p53 activity and uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (en) 2010-08-02 2022-01-18 瑟纳治疗公司 Inhibition of beta 1 gene expression using short interfering nucleic acids mediated by RNA interference of catenin (cadherin-associated protein)
LT2606134T (en) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (en) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibition of RNA-mediated gene expression using short interference nucleic acids (ANic)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
JP2014514321A (en) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション Insulin-like growth factor 1 receptor inhibitor
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
RU2660349C2 (en) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Compositions and methods for treatment of malignant tumour
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
MA53287A (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (en) * 1991-12-27 1993-07-27 Japan Tobacco Inc Proline derivative

Also Published As

Publication number Publication date
WO1996018643A1 (en) 1996-06-20
CA2204130A1 (en) 1996-06-20
FI971685A0 (en) 1997-04-18
CZ179097A3 (en) 1997-10-15
BR9509997A (en) 1997-12-30
MX9703957A (en) 1997-09-30
FI971685A7 (en) 1997-08-13
JPH10511935A (en) 1998-11-17
NO972526L (en) 1997-06-03
EP0797583A1 (en) 1997-10-01
TR199501568A2 (en) 1996-07-21
HUT77002A (en) 1998-03-02
IL116323A0 (en) 1996-03-31
AR001332A1 (en) 1997-10-22
FI971685L (en) 1997-08-13
SK74697A3 (en) 1997-11-05
PL320217A1 (en) 1997-09-15
PE38997A1 (en) 1997-10-02
NO972526D0 (en) 1997-06-03
AU4343796A (en) 1996-07-03

Similar Documents

Publication Publication Date Title
CO4700289A1 (en) TACHYCININ AMIDA ANTAGONISTS WHO HAVE TACHYCININ ANTAGONIST ACTIVITY
ES2112913T3 (en) N-PHENYLPIRAZOLES USEFUL AS INSECTICIDES AND ACARICIDES.
DE59108530D1 (en) Antimicrobial agents and substituted 2-cyclohexan-1-yl-amine derivatives and their preparation
ATE167470T1 (en) HETEROCYCLIC AMINE FOR THE THERAPY OF ASTHMA AND INFLAMMATION OF THE RESPIRATORY TRACT
IL135333A0 (en) Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same
DK0674641T3 (en) Pyrrolopyrimidines as CRF antagonists
PT750618E (en) OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
DE3868076D1 (en) HETEROCYCLIC DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND FUNGICIDES CONTAINING THEM AS ACTIVE INGREDIENTS.
DK0641328T3 (en) Bridged, azabicyclic derivatives as substance P antagonists
NO952397D0 (en) Substituted pyrazoles as CRF antagonists
DE69203104D1 (en) Manufacture of cellular elastomers and chemical compositions for their manufacture.
ATE180773T1 (en) N-SULFONYL-2-OXOINDOLE DERIVATIVES WITH AN AFFINITY FOR THE VASOPRESSIN AND/OR OCYTOCIN RECEPTORS
FI974447A0 (en) Semicarbazones having central nervous system activity and pharmaceutical preparations containing them
ATE156818T1 (en) POLYFLUORALKYLTHIOPOLY(ETHYLIMIDAZOLIUM) COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS BIOCIDAL AGENTS
ES2056783T3 (en) SUBSTITUTED DERIVATIVES OF BENZOIC ACID WITH CARDIOVASCULAR ACTIVITY.
ATE224T1 (en) 1,2-DIHYDRO-QUINOLINE-2-ONE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND MEDICATIONS CONTAINING THESE COMPOUNDS.
NO910958L (en) NEW CC-1065 ANALOGS WITH TWO CPI UNITS.
DE69229339D1 (en) CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PRODUCTION AND USE
ATE150735T1 (en) STORAGE STABLE ENCAPSULATED SODIUM PERCARBONATE AND METHOD FOR THE PRODUCTION THEREOF
ATE11134T1 (en) 1-(3-HALOGEN-2-PYRIDINYL)PIPERAZINE, PROCESS FOR THEIR PREPARATION AND MEDICATIONS CONTAINING THEM.
PT861250E (en) AMIDINE AND ISOTIOUREIA DERIVATIVES AS NITRIC OXIDE INHIBITORS
ATE37182T1 (en) IMIDAZOLINONES AND IMIDAZOLIDINTHIONES, PROCESSES FOR THEIR PREPARATION AND USE OF THESE COMPOUNDS AS HERBICIDES.
SE8500107D0 (en) NEW 8ALFA-ACYLAMINOERGOLINE
CO4761039A1 (en) FUNGICIDE MIXTURES CONTAINING CARBAMATES AND AMIDES OF CARBOXYLIC ACID
ATE144510T1 (en) N-(ISOCHINOLEIN-5-YL)-SULFONYL AZAZYKLOALKANES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME